Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Financial Calendar

March 28, 2024

2023 full year results
Financial Reports
2023 Half Year Report

2023 Half Year Report


2022 Annual Report

2022 Annual Report


2022 Annual Report

2022 Annual Report – European Single Electronic Format (ESEF) – Dutch only


2022 Half Year Report

2022 Half Year Report


2021 Annual Report

2021 Annual Report


2021 Annual Report

2021 Annual Report – European Single Electronic Format (ESEF) – Dutch only


2021 Half Year Report

2021 Half Year Report


2020 Annual Report

2020 Annual Report


2020 Half Year Report

2020 Half Year Report


2019 Annual Report

2019 Annual Report


2019 Statutory Annual Accounts

2019 Statutory Annual Accounts


2019 Half Year Report

2019 Half Year Report


2018 Annual Report

2018 Annual Report


2018 Statutory Annual Accounts

2018 Statutory Annual Accounts


PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES